8-K: Checkpoint Therapeutics Achieves FDA Alignment for Cosibelimab BLA Resubmission

Checkpoint Therapeutics has reached an agreement with the FDA on its strategy to resubmit its biologics license application for cosibelimab, a potential treatment for advanced skin cancer.

Summary

• Checkpoint Therapeutics has aligned with the FDA on its resubmission strategy for the biologics license application (BLA) for cosibelimab.
• The company plans to resubmit the BLA mid-year, seeking approval for cosibelimab as a treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).
• The FDA's previous complete response letter (CRL) in December 2023 cited issues related to a third-party contract manufacturing organization (CMO), not the clinical data, safety, or labeling of cosibelimab.
• Checkpoint is also developing olafertinib, a third-generation EGFR inhibitor, for non-small cell lung cancer.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the alignment with the FDA and the planned BLA resubmission. However, the previous CRL and the risks associated with manufacturing and regulatory approval temper the overall optimism.

Positives

• The FDA has aligned with Checkpoint on the BLA resubmission strategy, indicating a clear path forward.
• The previous CRL did not raise concerns about the clinical data, safety, or labeling of cosibelimab.
• Cosibelimab has a potentially favorable safety profile compared to existing anti-PD-1 therapies.
• Cosibelimab has a two-fold mechanism of action that could lead to enhanced efficacy.

Negatives

• The company previously received a complete response letter (CRL) from the FDA regarding the cosibelimab BLA.
• The CRL was due to issues at a third-party contract manufacturing organization (CMO).
• There is a risk that the third-party CMO may not pass future regulatory inspections.

Risks

• The third-party CMO may not pass regulatory inspections or meet deadlines.
• Clinical data is subject to audit and verification, which could result in changes to previously published data.
• Safety issues could emerge when the full safety dataset is analyzed.
• Regulatory authorities may not accept the application based on Phase 1 clinical trial data.
• The clinical results may not support regulatory approval or commercial success.
• The company faces risks related to manufacturing, financing, and strategic agreements.
• The company needs substantial additional funds.
• The Russia/Ukraine conflict and COVID-19 pandemic could delay milestones.

Future Outlook

Checkpoint plans to resubmit the BLA for cosibelimab mid-year and is working to address all approvability deficiencies outlined in the CRL. The company is also continuing development of olafertinib for non-small cell lung cancer.

Management Comments

• James F. Oliviero, President and CEO, stated they are pleased to have reached alignment with the FDA on the BLA resubmission strategy.
• Oliviero also mentioned they are eager to resubmit the BLA and potentially bring a new immunotherapy treatment option to patients with advanced cSCC.

Industry Context

This announcement is significant as it indicates progress in the development of a new immunotherapy treatment for cSCC, a type of skin cancer with limited treatment options. The successful resubmission and approval of cosibelimab could provide a new treatment option for patients and potentially give Checkpoint a competitive advantage in the oncology market.

Comparison to Industry Standards

• Cosibelimab is being developed as a potential best-in-class anti-PD-L1 antibody, which would position it against existing anti-PD-1 therapies like pembrolizumab (Keytruda) and nivolumab (Opdivo).
• The company is highlighting a potentially favorable safety profile and a two-fold mechanism of action as differentiators compared to existing treatments.
• The focus on addressing manufacturing issues identified by the FDA is critical, as these are common hurdles in the pharmaceutical industry, and successful resolution is essential for approval.

Stakeholder Impact

• Shareholders may react positively to the news of FDA alignment and the planned BLA resubmission.
• Patients with advanced cSCC could benefit from a new treatment option if cosibelimab is approved.
• Employees of Checkpoint Therapeutics will be involved in the resubmission process and the ongoing development of cosibelimab and olafertinib.

Next Steps

• Checkpoint plans to resubmit the BLA for cosibelimab mid-year.
• The company will continue to work with its third-party CMO to address the issues raised in the CRL.
• Checkpoint will continue the development of olafertinib for non-small cell lung cancer.

Key Dates

Keywords

cosibelimab, FDA, BLA, cutaneous squamous cell carcinoma, cSCC, immunotherapy, checkpoint therapeutics, olafertinib, contract manufacturing organization, anti-PD-L1 antibody